0001104659-23-119186.txt : 20231116
0001104659-23-119186.hdr.sgml : 20231116
20231116174656
ACCESSION NUMBER: 0001104659-23-119186
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231114
FILED AS OF DATE: 20231116
DATE AS OF CHANGE: 20231116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEISS MICHAEL S
CENTRAL INDEX KEY: 0001038977
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35366
FILM NUMBER: 231415744
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205157386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
FORMER COMPANY:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
4
1
tm2330934-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-11-14
0
0001429260
Fortress Biotech, Inc.
FBIO
0001038977
WEISS MICHAEL S
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301
BAY HARBOR ISLANDS
FL
33154
1
1
0
0
See Remarks
0
COMMON STOCK, PAR VALUE $0.001
2023-11-14
4
P
0
147058
1.70
A
1130520
D
Warrants to purchase Common Stock
1.70
2023-11-14
4
P
0
147058
0.00
A
2023-11-14
2028-11-14
Common Stock
147058
147058
D
Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70.
Executive Vice Chairman, Strategic Development
/s/ Samuel Berry, Attorney-in-Fact
2023-11-16